Skip to main content
. Author manuscript; available in PMC: 2020 Apr 13.
Published in final edited form as: J Alzheimers Dis. 2019;72(2):467–478. doi: 10.3233/JAD-190779

Fig. 1.

Fig. 1.

Unchanged hippocampal Aβ deposition in MK0677-treated 5xFAD mice. A) Daily MK0677 intraperitoneal Injection on mice. B) 3.0 mg/kg MK0677 treatment had significant impact on 5xFAD lifespan. Two-way ANOVA followed by Bonferroni post hoc analysis. **p < 0.01 between nonTg saline and 5xFAD 3.0 mg/kg MK0677groups; NS, no significant difference between nonTg saline and 5xFAD 1.5 mg/kg MK0677 groups, n = 4–8 mice. C) Mouse body weight remained the same during 1.5 mg/kg MK0677 treatment. NS, no significant difference among all the groups, n = 4–8 mice. D1, D2) 1.5 mg/kg MK0677 treatment had no influence on amyloid plaque-occupied volume on 5xFAD mice. Unpaired Student’s t-test. t = 0.3613, NS, not significant, n = 4 mice per group. D2) 1.5 mg/kg MK0677 treatment did not change the single amyloid plaque volume in mice hippocampi. Unpaired Student’s t-test. t = 0.6155, NS, not significant, n = 4 mice each group. D3) Representative images for amyloid plaque staining. Scale bar = 100 μm.